IIFL Securities Stock Idea: Buy Sun Pharma Adv.res.co.ltd with Target Rs 441

IIFL Securities recommends buying Sun Pharma Advanced Research Company Limited (SPARC) with a target price of Rs. 441, representing a potential upside of around 3%. The current market price of SPARC is Rs. 428. The company's strong product pipeline, robust financials, and strategic initiatives are cited as key reasons for the buy rating. SPARC is a leading global specialty pharmaceutical company with a focus on dermatology, ophthalmology, and oncology.

About Sun Pharma Adv.res.co.ltd:

Sun Pharmaceutical Advanced Research Company Limited (SPARC) is a leading Indian pharmaceutical company engaged in the research, development, manufacture, and marketing of generic and branded drugs. Listed on the National Stock Exchange (NSE) of India, SPARC is a subsidiary of Sun Pharmaceutical Industries Limited, one of the largest pharmaceutical companies in India. The company focuses on developing innovative and affordable drugs in therapeutic areas such as cardiovascular, diabetes, and central nervous system disorders. SPARC has a strong pipeline of products under development and a global presence in over 100 countries.

52 Week Price Trend:

Sun Pharma Advanced Research Company Limited (SPARC), a subsidiary of Sun Pharmaceuticals, has witnessed a significant rise in its stock price over the past 52 weeks. Currently trading at Rs 428, SPARC's share price has soared by over 160% from its 52-week low of Rs 160.5, indicating a strong bullish trend. However, the stock is slightly below its 52-week high of Rs 423.6. Investors should monitor SPARC's performance closely, considering its strong growth trajectory and the overall market conditions.

Stratzy's MOST Analysis:

SPARC's BB- rating from Stratzy's MOST framework indicates medium fundamental risks. This rating is based on an assessment of the company's management, outlook, safety, and trend. Specifically, the framework may have identified weaknesses or concerns in one or more of these areas. For instance, the company's management may lack experience or stability, the outlook may be uncertain due to industry headwinds, or the company's financial position may raise safety concerns. Investors should consider these risks carefully before investing in SPARC.

Fundamental and Technical information provided in this blog were last updated on 05 Apr, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.